ライフサイエンスコーパス: preerythrocytic

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ation exposes the host to antigens from both preerythrocytic and blood stages, and induced immunity m

2 ect protective biological effects induced by preerythrocytic and/or blood-stage candidate vaccines if

3 ing significant efficacy when expressing the preerythrocytic antigen insert multiple epitope-thrombos

4 part to infrequent high-level antibodies to preerythrocytic antigens and AMA-1.

5 date subunit malaria vaccines expressing six preerythrocytic antigens linked together to produce a 32

6 terile protective immune responses targeting preerythrocytic antigens.

7 h-level immunoglobulin G (IgG) antibodies to preerythrocytic circumsporozoite protein (CSP) and liver

8 se data introduce a new target of protective preerythrocytic immune responses, PyHEP 17 and its P. fa

9 ce are more susceptible to Plasmodium yoelii preerythrocytic infection than BALB/cJ mice.

10 impanzee adenovirus 63 (ChAd63) encoding the preerythrocytic insert multiple epitope thrombospondin-r

11 two; all vaccines express parts of the same preerythrocytic malaria antigen, the Plasmodium berghei

12 esence of adaptive cell-mediated immunity to preerythrocytic malaria antigens in volunteers from Mali

13 of an early immune response directed against preerythrocytic malaria parasites that are required for

14 cted as a first step in the development of a preerythrocytic malaria vaccine.

15 evaluate liver-stage protection by candidate preerythrocytic malaria vaccines.

16 approach for identifying target antigens for preerythrocytic malaria vaccines.

17 Fourteen epitopes of preerythrocytic malarial antigens known to mediate cytot

18 ith unstable transmission, IgG antibodies to preerythrocytic P. falciparum antigens vary in subjects

19 t of early immunity directed against malaria preerythrocytic parasites and suggest that gammadelta T

20 ng vaccine classes currently in development: preerythrocytic (PEV), blood stage (BSV), and transmissi

21 (IgG) antibodies to three vaccine candidate preerythrocytic Plasmodium falciparum antigens were eval

22 a should facilitate our understanding of the preerythrocytic Plasmodium life cycle stages and the dev

23 ritical effector cells in protection against preerythrocytic stage malaria, including the potent prot

24 laria vaccine that prevents infection at the preerythrocytic stage.

25 esponses against a pool of peptides from the preerythrocytic-stage antigen, PkCSP.

26 ia species Plasmodium knowlesi including two preerythrocytic-stage antigens, the circumsporozoite pro

27 lii sporozoites or with plasmid DNA encoding preerythrocytic-stage P. yoelii antigens.

28 the HIV PIs lopinavir and saquinavir affect preerythrocytic-stage parasite development in vitro.

29 with a mixture of DNA plasmids encoding two preerythrocytic-stage proteins and two erythrocytic-stag

30 at ChAd63 and MVA expressing PvTRAP are good preerythrocytic-stage vaccine candidates with potential

31 The effect on preerythrocytic stages has not yet been investigated.

32 We then evaluated the effect of HIV PIs on preerythrocytic stages in vivo using the rodent parasite

33 cation and cloning of genes expressed in the preerythrocytic stages lag far behind.

34 t parasite play a protective role during the preerythrocytic stages of malaria.

35 at CD8(+) T cells play in protection against preerythrocytic stages of malaria; however, there is mou

36 The latter approach completely bypasses preerythrocytic stages, enabling a direct comparison of

37 throughout the life cycle, with emphasis on preerythrocytic stages.

38 panel of HIV PIs in vitro for effects on the preerythrocytic stages.

39 d protection is mediated by immunity against preerythrocytic stages.

40 have been widely used to assess efficacy of preerythrocytic vaccine candidates in small proof-of-con

41 protein, FMP011, has been manufactured as a preerythrocytic vaccine to induce an immune response tha

42 ite vaccine, the "gold standard" for malaria preerythrocytic vaccines, was sporozoite-neutralizing an

43 ium life cycle stages and the development of preerythrocytic vaccines.

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。